In a sign that hopes for quick medical benefits from stem cells are fading, ES Cell International (ESI)–a company established with fanfare in Singapore 7 years ago–is halting work on human embryonic stem (hES) cell therapies.
The company was attempting to turn hES cells into insulin-producing cells to treat diabetes and cardiac muscle cells to counter congestive heart failure. Both conditions represent major markets with unmet clinical needs, but making well-functioning insulin-producing cells “proved really difficult,” Colman says.
Another sign that all the money spent on enbryonic stem cells is wasted. If we’re going to spend money on what works: adult stem cell therapies.